{"disease":{"id":"inoperable-disease","name":"inoperable disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04780932","title":"Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06483347","title":"Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT05817604","title":"Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Consorci Sanitari de Terrassa","has_results":false},{"nct_id":"NCT05418543","title":"CH-EUS in Diagnosis of Inoperable Bile Duct Tumors","phase":"NA","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor","has_results":false},{"nct_id":"NCT07311057","title":"Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":20,"lead_sponsor_name":"Daryoush Hamidi Alamdari, PhD","has_results":false},{"nct_id":"NCT07311070","title":"Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":20,"lead_sponsor_name":"Daryoush Hamidi Alamdari, PhD","has_results":false},{"nct_id":"NCT04652206","title":"Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"Scandion Oncology A/S","has_results":false},{"nct_id":"NCT04685499","title":"Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":true}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}